CRISPR is the ultimate child star in the biomedical universe.

Just six years old, the gene editing prodigy is now the subject of multiple clinical trials that aim to push the lab tech into the real world.

I can’t stress how abnormal this is: CRISPR’s awkwardly-named predecessors—zinc-finger nucleases and TALENS—suffered through “bench-to-bedside” hell as it took more than a decade before they even got the FDA go-ahead for clinical trials. In 2017, a 44-year-old man received the first-ever dose of gene therapy—in the form of zinc-finger nucleases—that targeted a deficient gene in his liver…”